By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses
Ridgeback Biotherapeutics is a private company developing antivirals for untreated and pandemic diseases, with support from partnerships and public funding. It is currently partnering with Merck in Phase 2 development of a ribonucleoside analog, coded MK-4482, an oral drug for treating COVID-19 infection by inhibiting viral replication. Another lead product, ansuvimab, is under priority review by the FDA for treating Ebola.